ResMed appointed its former vice president of information technology, Bobby Ghoshal, as chief technology officer. Ghoshal most recently served as chief operating officer at cloud-based SaaS provider Brightree, which was acquired by ResMed in 2016.
A combination test for pneumococcal and meningococcal meningitis was launched by Irish company HiberGene Diagnostics. The test takes 40 minutes to provide results and is expected to cover 90% of bacterial meningitis cases.
The Lightvision near-infrared fluorescence imaging system was released by Shimadzu for use in supporting treatment of patients with breast cancer. The system, which comes with built-in high-definition sensors, provides visualization of lymph and blood vessels by detecting the emission of near-infrared fluorescent light from the indocyanine green it administered through the vessels.
European regulators gave Applied BioCode CE mark approval for its BioCode MDx 3000 high-volume, automated PCR-based molecular diagnostics platform and its Gastrointestinal Pathogen Panel. The platform takes about 3.5 hours to process up to 94 samples, while the panel identifies the nucleic acids of 18 infectious diarrhea-causing bacteria, parasites and viruses.
GlaxoSmithKline's triplet therapy Trelegy Ellipta, or fluticasone furoate/umeclidinium/vilanterol, was approved by the FDA as a long-term, once-daily treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. The drug, from which the boxed warning was removed, was previously approved in patients with COPD who receive a fixed-dose combination of FF and VI and require additional treatment for airflow obstruction or who receive UMEC and a fixed-dose combination of FF and VI.
Otsuka Pharmaceutical's Jynarque, or tolvaptan, was approved by the FDA for use to slow kidney function decline in patients with rapidly progressing autosomal dominant polycystic kidney disease.
Alnylam Pharmaceuticals provided an update on new data from its late-stage APOLLO study evaluating patisiran as a treatment for hereditary ATTR amyloidosis at the 2018 annual meeting of the American Academy of Neurology. The results showed an approximate decrease of 50% in the composite rate of all-cause hospitalization and mortality over a period of 18 months in patients treated with patisiran versus patients who received placebo.
Moleculin Biotech said it is preparing to begin commercial production of its leukemia drug Annamycin in a deal with Italy's BSP Pharmaceuticals. No financial details of the contract were disclosed.
A letter of intent was signed by Precision Therapeutics, acquiring the remaining 75% equity stake in Helomics. The acquisition will give Precision full access to Helomics' D-Chip database, which uses artificial intelligence-powered bioinformatics to generate insights from the deidentified clinical test data of tumor responses to drugs.